Intravenous immune globulin use in Canada

Canadian Journal of Clinical Pharmacology

Volumn 10, Issue 1, 2003, Pages 11-16

  Hanna, Kim ^a   Poulin Costello, Melanie ^b   Preston, Mark ^b   Maresky, Neil ^b  

^a BAYER CORPORATION   (United States)

^b NONE

Author keywords

Appropriate use; Intravenous immune globulin; Off label use; Prescribing

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BANK; CANADA; CHILDHOOD DISEASE; COMPLEMENT ACTIVATION; DRUG EFFECT; DRUG TOLERABILITY; DRUG USE; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION PREVENTION; PRACTICE GUIDELINE; PRESCRIPTION; PROSPECTIVE STUDY; REVIEW; TREATMENT INDICATION; VIRUS INFECTION;

EID: 0037572250     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Pappenhagen A, Lundblad JL, Schroeder DD. Pharmaceutical composition comprising intravenously injectable modified serum globulin, its production and use. US Patent 3,903,262, 1975.
2. Schroeder DD, Tankersley DL, Lundblad JL. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction. Vox Sang 1981;40:373-82.
3. Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin for antibody deficiency. Clin Exp Immunol 1979;36:237-43.
4. Pirofsky B, Anderson CJ, Bardana EJ. Therapeutic and detrimental effects of intravenous immunoglobulin therapy. In: Alving BM, Finlayson JS, eds. Proceedings of a workshop on immunoglobulins: Characterizations and uses of intravenous preparations. Bureau of Biologics, FDA, National Heart, Lung, and Blood Institute NIH. October 30-31, 1979. DHHS Publication No FDA-80-9005. Washington: US Government Printing Office, 1980:15-22.
5. Ochs HD, Buckley RH, Pirofsky B, et al. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet 1980:ii:1158-9.
6. Clarkson SB, Bussel JB, Kimberly RP, Valinsky JE, Nachman RL, Unkeless JC. Treatment of refactory immune thrombocytopenic purpura with an anti Fc-gamma receptor antibody. N Engl J Med 1986;314:1236-9.
7. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62:480-6.
8. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989;74:2414-7.
9. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor FVIII (anti-haemophilic factor) by high dose intravenous immunoglobulin. Lancet 1984;ii:765-6.
10. Basta M, Langlois PF, Marques M, Frank MM, Fries LE. High dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989;74:326-33.
11. Frank MM, Basta M, Fries LE. The effects of intravenous immunoglobulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1991;62:882-6.
12. Infectious Diseases and Immunization Committee, Canadian Paediatric Society. Intravenous immune globulin use in children. CMAJ 1992;146:121-4.
13. Pirofsky B, Kinzey DM. Intravenous immune globulins: A review of their uses in selected immunodeficiency and autoimmune disease. Drugs 1992;43:6-14.
14. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-75.
15. Rousell RH, Pennington JE. An historical overview of immunoglobulin therapy. In: IPL Yap, ed. Clinical Applications of Intravenous Immunoglobulin Therapy. New York: Churchill Livingstone Inc, 1992:1-15.
16. Cohn E. The separation of blood into fractions for therapeutic value. Ann Intern Med 1947;26:341.
17. Rivet C, CBAACd sang. Utilization management of albumin and intravenous immune globulin. Canadian Apheresis Group Bulletin 1995:7-8.
18. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273:1865-70.
19. Health, NIO. Intravenous immunoglobulin. JAMA 1990;24:3189-93.
20. Therapeutics, ACo. ASHP therapeutic guidelines for intravenous immune globulin. Clin Pharm 1992;11:117-36.
21. Keller T, McGrath K, Newland A, Gatenby P, Cobcroft R, Gibson J. Indications for use of intravenous immunoglobulin. Med J Aust 1993;159:204-6.
22. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-92.
23. Bril V, Allenby K, Midroni G, O'Connor PW, Vajsar J. IVIG in neurology - evidence and recommendations. Can J Neurol Sci 1999;26:139-52.
24. Roifman C, Balter M, Blanchette V, Cardella C, Feasby T, Lipton J, eds. Present and future uses of intravenous immune globulin (IVIG): A canadian multidisciplinary consensus-building initiative. (Newsletter). Toronto: McLean Hunter Healthcare, 1997.
25. Steihm ER. Appropriate therapeutic use of immunoglobulin. Transfusion Med Rev 1996;10:203-21.
26. Van der Meche F, Van Doorn P. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 1997;20:136-47.
27. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126:721-30.